Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

S100B measurement in the maternal blood: a new promising tool for fetal well-being/distress monitoring?

Clinical chemistry and laboratory medicine·2026
Same author

Placental microRNAs as molecular links between maternal metabolic health and neonatal outcomes.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2026
Same author

Rapid assessment of feeding intolerance: a systematic approach to reduce time to full enteral feeding in preterm infants.

Frontiers in pediatrics·2026
Same author

S100B urine levels are gestational age, birthweight, delivery mode and gender-dependent in healthy newborns.

Clinical chemistry and laboratory medicine·2026
Same author

Impact of touch interventions on brain activity in moderately preterm infants: study protocol for a pilot randomised controlled trial.

BMJ open·2025
Same author

The Estimated Intake of S100B Relates to Microbiota Biodiversity in Different Diets.

Biomolecules·2025

Related Experiment Video

Updated: Jun 11, 2026

Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods
09:04

Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods

Published on: September 10, 2018

S100B testing in pregnancy.

Fabrizio Michetti1, Diego Gazzolo

  • 1Institute of Anatomy and Cell Biology, Catholic University, Largo Francesco Vito 1, I-00168, Rome, Italy. fabrizio.michetti@rm.unicatt.it

Clinica Chimica Acta; International Journal of Clinical Chemistry
|August 21, 2003
PubMed
Summary

The S100B protein shows promise as a biomarker for detecting fetal brain damage during prenatal and perinatal periods. Elevated S100B levels in amniotic fluid and cord blood indicate neurological issues, aiding in early diagnosis and intervention.

More Related Videos

High Frequency Ultrasound for the Analysis of Fetal and Placental Development In Vivo
06:43

High Frequency Ultrasound for the Analysis of Fetal and Placental Development In Vivo

Published on: November 8, 2018

Semiconductor Sequencing for Preimplantation Genetic Testing for Aneuploidy
09:03

Semiconductor Sequencing for Preimplantation Genetic Testing for Aneuploidy

Published on: August 25, 2019

Related Experiment Videos

Last Updated: Jun 11, 2026

Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods
09:04

Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods

Published on: September 10, 2018

High Frequency Ultrasound for the Analysis of Fetal and Placental Development In Vivo
06:43

High Frequency Ultrasound for the Analysis of Fetal and Placental Development In Vivo

Published on: November 8, 2018

Semiconductor Sequencing for Preimplantation Genetic Testing for Aneuploidy
09:03

Semiconductor Sequencing for Preimplantation Genetic Testing for Aneuploidy

Published on: August 25, 2019

Area of Science:

  • Neuroscience
  • Biochemistry
  • Prenatal Medicine

Background:

  • Neurological abnormalities in children often originate prenatally or perinatally.
  • Understanding the timing of adverse insults is crucial for prevention strategies.
  • Current diagnostic methods rely on indirect markers like ultrasound and blood gases.

Purpose of the Study:

  • To evaluate the S100B protein as a specific biomarker for fetal brain damage.
  • To investigate the utility of S100B in prenatal and perinatal medicine.
  • To explore the correlation of S100B levels with gestational age and therapeutic interventions.

Main Methods:

  • Measurement of S100B protein concentrations in amniotic fluid and cord blood.
  • Analysis of S100B levels in high-risk pregnancies.
  • Monitoring S100B changes during maternal-antenatal therapies (e.g., NO, glucocorticoids).

Main Results:

  • S100B protein concentration was elevated in amniotic fluid and cord blood of fetuses with brain damage.
  • S100B measurements effectively monitored the impact of maternal therapies.
  • S100B concentrations showed patterns related to gestational age in amniotic fluid, cord blood, and placenta.

Conclusions:

  • S100B protein is a reliable and sensitive biomarker for detecting prenatal and perinatal brain injury.
  • S100B facilitates monitoring of therapeutic interventions and understanding fetal neurodevelopment.
  • This marker offers a direct indicator of nervous system cell damage, improving diagnostic capabilities.